Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1441-1460 of 1,743 trials

Inflammatory Disorders: New Imaging Tracer 18F-AlF-FAPI-74

We are studying a new imaging tracer to see if it can better diagnose inflammatory disorders compared to the standard tracer. This trial includes patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis.

Fever of Unknown OriginIgG4-Related DiseaseAxial Spondyloarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyRheumatology

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Bleeding Treatment in Thrombocytopenic Patients: FORMAT Study

We are studying whether adding fibrinogen to platelet transfusions helps patients with low platelet counts after chemotherapy stop bleeding. This trial will evaluate the effectiveness and safety of this treatment approach.

Blood Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Metastatic Colorectal Cancer: JNJ-89402638 Study

We are testing a new drug, JNJ-89402638, for patients with metastatic colorectal cancer. This study aims to evaluate its safety and how it may help in treating this advanced stage of cancer.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Erlotinib Distribution Study

We are exploring how drug transporters affect the distribution of erlotinib in the brain and other organs in humans. This research may help improve treatment strategies for patients using this medication.

Cancer>2 yearsSafety phase (I)Oncology

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Advanced Liver Cancer: BAY 3547926 Study

We are investigating the safety and effectiveness of a new drug, BAY 3547926, for people with advanced liver cancer. This study aims to understand how well it works in treating this condition.

Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Epstein-Barr Virus Diseases: Tabelecleucel Treatment

We are studying a new treatment called tabelecleucel for individuals with Epstein-Barr virus-associated diseases. The goal is to see if it can improve health outcomes compared to current options.

EBV-Related Lymphoproliferative Disorder>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyInfectious DiseasesOncology

Immune-Related Rheumatological Events in Cancer Patients

We are collecting data on how to better diagnose and manage joint and muscle issues caused by cancer treatments. This study involves multiple centers to improve care for patients receiving checkpoint inhibitors.

Cancer (all types)>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyRheumatology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterologyOncology

Status Epilepticus Treatment in Elderly Patients

We are investigating a new treatment for established status epilepticus in older adults. This study aims to provide evidence on how effective this treatment is for this vulnerable population.

Status Epilepticus>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Stroke Care: HOPE Study on Blood Pressure Management

We are comparing standard blood pressure management to a personalized approach after mechanical thrombectomy for acute ischemic stroke patients. The goal is to see which method better supports recovery and brain health.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Bronchopulmonary Dysplasia: Stem Cell Treatment for Preterm Infants

We are studying the safety of umbilical cord stem cells in preterm babies with bronchopulmonary dysplasia. This research aims to see if the treatment can help improve their lung health and overall development.

Bronchopulmonary Dysplasia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPediatricsPulmonology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

COPD: Atorvastatin for Reducing Exacerbations

We are studying whether atorvastatin can help reduce flare-ups in smokers with chronic obstructive pulmonary disease. The trial also looks at how this medication may affect lung function and quality of life.

Chronic Obstructive Pulmonary Disease>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology